Meta-Analysis of Prostate-Specific Antigen and Digital Rectal Examination as Screening Tests for Prostate Carcinoma

References

1. ↵
   Greenelee RT, Hill-Harmon MB, Murry T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15–36.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   Godley PA. Prostate cancer screening: promise and peril—a review. Cancer Detect Prev 1999; 23: 316–24.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   Jubelirer SJ, Tierney JP, Oliver S, et al. The value of prostatic specific antigen in prostate cancer screening in the community. W Va Med J 1994; 90: 140–2.

   OpenUrl
4. ↵
   Marwick C. Global review of diet and cancer links available. JAMA 1997; 278: 1650–1.

   OpenUrlCrossRefPubMed
5. ↵
   Maattanen L, Auvinen A, Stenman UH, et al. European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer 1999; 79: 1210–4.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   Kuriyama M, Wang MC, Papsidero LD, et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980; 40: 4658–62.

   OpenUrlAbstract/FREE Full Text
7. ↵
   Higashihara E, Nutahara K, Kojima M, et al. Significance of free prostate-specific antigen and gamma-seminoprotein in the screening of prostate cancer. Prostate Suppl 1996; 7: 40–7.

   OpenUrlPubMed
8. ↵
   Jewett HJ, Bridge RW, Gray GF Jr, Shelley WM. The palpable nodule of prostatic cancer. Results of 15 years after radical excision. JAMA 1968; 203: 403–6.

   OpenUrlCrossRefPubMed
9. ↵
   Osterling JE. Early detection of prostate cancer. Decreasing the mortality rate. Minn Med 1996; 79: 46–9.

   OpenUrl
10. Guide to clinical preventive services. 2nd ed. Report of the US Preventive Services Task Force. Baltimore, Md: Williams & Wilkins 1996: 119–34.
11. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993; 119: 914–23.

    OpenUrlPubMedWeb of Science
12. Woolf HS. Screening for prostate cancer with prostate-specific antigen: an examination of evidence. N Engl J Med 1995; 333: 1401–5.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    Zoorob R, Anderson R, Cefalu C, Sidani M. Cancer screening guidelines. Am J Fam Physician 2001; 63: 1101–12.

    OpenUrl
14. ↵
    Bangma CH, Kranse R, Blijenberg BG, Schroder F. The value of screening tests in the detection of prostate cancer. Part II: retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology 1995; 46: 779–84.

    OpenUrlCrossRefPubMedWeb of Science
15. Brett TD. An analysis of digital rectal examination and serum-prostate-specific antigen in the early detection of prostate cancer in general practice. Fam Pract 1998; 15: 529–33.

    OpenUrlAbstract/FREE Full Text
16. Bretton PR. Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study. South Med J 1994; 87: 720–3.

    OpenUrlCrossRefPubMed
17. ↵
    Gustafsson O, Mansour E, Norming U, Carlsson A, Tomblom M, Nyman CR. Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer—a study of a randomly selected population of 2,400 men. Scand J Urol Nephrol 1998; 32: 373–7.

    OpenUrlPubMed
18. Horninger W, Reissigl A, Rogatsch H, et al. Prostate cancer screening in Tyrol, Australia: experience and results. Eur Urol 1999; 35: 523–38.

    OpenUrlPubMed
19. Imai K, Ichinose Y, Kubota Y, et al. Clinical significance of prostate specific antigen for early stage prostate cancer detection. Jpn J Clin Oncol 1994; 24: 160–5.

    OpenUrlAbstract/FREE Full Text
20. Imai K, Ichinose Y, Kubota Y, Yamanaka H, Sato J. Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. J Urol 1995; 154: 1085–9.

    OpenUrlCrossRefPubMedWeb of Science
21. Reissigl A, Pointner J, Horninger W, et al. PSA-based screening for prostate cancer in asymptomatic younger males: pilot study in blood donors. Prostate 1997; 30: 20–5.

    OpenUrlCrossRefPubMedWeb of Science
22. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostatic specific antigen and its complex with alpha1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994; 344: 1594–8.

    OpenUrlCrossRefPubMedWeb of Science
23. Tsukamoto T, Kumamoto Y, Masumori N, et al. Mass screening for prostate carcinoma: a study in Hokkaido, Japan. Eur Urol 1995; 27: 177–81.

    OpenUrlPubMed
24. ↵
    Cochran WG. Sampling techniques. 3rd ed. New York: John Wiley & Sons, 1977: 89–96.
25. ↵
    Woolf HS. Prostate cancer: to screen or not to screen? Commentary. Oncology 1997; 11: 451–2.

    OpenUrl
26. ↵
    Tornblom M, Norming U, Adolfsson J, et al. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3 ng/mL. Urology 1999; 53: 945–50.

    OpenUrlCrossRefPubMedWeb of Science
27. ↵
    Lodding P, Aus G, Bergdahl S, et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/mL prostate-specific antigen. J Urol 1998; 159: 899–903.

    OpenUrlCrossRefPubMedWeb of Science
28. ↵
    Svetec D, Thompson IM. PSA screening—current controversy. Ann Oncol 1998; 9: 1283–8.

    OpenUrlAbstract/FREE Full Text
29. ↵
    Scardino PT. Early detection of prostate cancer. Urol Clin North Am 1989; 16: 635–55.

    OpenUrlPubMedWeb of Science
30. ↵
    Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group. Eur J Cancer 1999; 35: 262–71.
31. ↵
    Zappa M, Ciatto S, Bonardi R, Mazzotta A. Overdiagnosis of prostate carcinoma by screening: An estimate based on the results of the Florence screening pilot study. Ann Oncol 1998; 9: 1297–1300.

    OpenUrlAbstract/FREE Full Text
32. ↵
    Brawer MK. prostate-specific antigen. Diagn Clin Testing 1990; 28: 16–21.

    OpenUrl
33. ↵
    Oesterling JE. Prostate-specific antigen. Cancer 1995; 75: 1795–1804.

    OpenUrlCrossRef
34. ↵
    Statistical abstract of the United States. 17th ed. US Department of Commerce, Economics and Statistics Administration, Bureau of the Census. Lantham, Md: Bernan Press, 1997: 15.
35. ↵
    de Koning HJ, Auvinen A, Berenguer Sanchez AB, et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002; 97: 237–44.

    OpenUrlCrossRefPubMedWeb of Science